A clinical-stage biopharmaceutical organization with a focus on cardiovascular disease.

All of the clinical sites in the trial are in the U.S. The principal endpoint in the trial may be the % change in triglyceride level from baseline to week 12. ‘We are delighted that the ANCHOR study has had the opportunity to complete the individual randomization process prior to the end of 2010,’ said Joseph S. Zakrzewski, Executive Chairman and CEO of Amarin. ‘Following very positive results of the lately reported MARINE study in which AMR101 demonstrated that it reduced triglyceride levels without increasing LDL-C in sufferers with very high triglycerides , the ANCHOR research evaluates AMR101 in a different and bigger patient population.Under the conditions of the agreement, OMJPI could have the option to permit assays to newly determined targets from the BSi, and, in trade, OMJPI will share device compounds with BSI experts for biological focus on identification and validation. Related StoriesArticle explores viewpoints on part of moderate cognitive impairment in Parkinson's diseaseAdvances entirely mount human brain imaging: an interview with Patrick Myles, President, Huron Digital PathologyNew tool can help diagnose and deal with Parkinson's disease in first stages’By merging our vast reservoir of understanding and talent, the mind Science Institute expectations to start another era of neuropsychiatric pharmaceuticals down the pipeline by merging complimentary skills and experience of academic and pharmaceutical scientists,’ says John Griffin, M.D., director of the BSi, University Distinguished Provider Professor of the Division of Neurology, and professor of pathology and neuroscience at the Johns Hopkins University School of Medication.